WO2023015533A1 - 一种合成肽以及它们的美容组合物或药用组合物及用途 - Google Patents
一种合成肽以及它们的美容组合物或药用组合物及用途 Download PDFInfo
- Publication number
- WO2023015533A1 WO2023015533A1 PCT/CN2021/112345 CN2021112345W WO2023015533A1 WO 2023015533 A1 WO2023015533 A1 WO 2023015533A1 CN 2021112345 W CN2021112345 W CN 2021112345W WO 2023015533 A1 WO2023015533 A1 WO 2023015533A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agents
- acceptable salt
- agent
- cosmetic
- optionally
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 216
- 239000002537 cosmetic Substances 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 52
- 150000003839 salts Chemical class 0.000 claims abstract description 88
- 239000003795 chemical substances by application Substances 0.000 claims description 136
- 210000004027 cell Anatomy 0.000 claims description 84
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 57
- 239000000284 extract Substances 0.000 claims description 52
- 230000015572 biosynthetic process Effects 0.000 claims description 49
- 238000003786 synthesis reaction Methods 0.000 claims description 48
- 210000003491 skin Anatomy 0.000 claims description 46
- -1 esterylalkyl Chemical group 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 43
- 210000002950 fibroblast Anatomy 0.000 claims description 35
- 239000007787 solid Substances 0.000 claims description 28
- 230000008439 repair process Effects 0.000 claims description 26
- 229940024606 amino acid Drugs 0.000 claims description 25
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 230000035755 proliferation Effects 0.000 claims description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 108010035532 Collagen Proteins 0.000 claims description 19
- 102000008186 Collagen Human genes 0.000 claims description 19
- 229920001436 collagen Polymers 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 17
- 238000013268 sustained release Methods 0.000 claims description 17
- 239000012730 sustained-release form Substances 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000004744 fabric Substances 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000004745 nonwoven fabric Substances 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 210000004400 mucous membrane Anatomy 0.000 claims description 12
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 229920000620 organic polymer Polymers 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 11
- 206010051246 Photodermatosis Diseases 0.000 claims description 10
- 230000035876 healing Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 230000008845 photoaging Effects 0.000 claims description 10
- 230000009759 skin aging Effects 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 231100000241 scar Toxicity 0.000 claims description 9
- 102000016942 Elastin Human genes 0.000 claims description 8
- 108010014258 Elastin Proteins 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 8
- 229920002549 elastin Polymers 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 239000004530 micro-emulsion Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 206010052428 Wound Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 210000001789 adipocyte Anatomy 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 239000000419 plant extract Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 230000037303 wrinkles Effects 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 206010040943 Skin Ulcer Diseases 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 230000008591 skin barrier function Effects 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 230000003779 hair growth Effects 0.000 claims description 4
- 208000000069 hyperpigmentation Diseases 0.000 claims description 4
- 230000003810 hyperpigmentation Effects 0.000 claims description 4
- 239000003410 keratolytic agent Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000000865 liniment Substances 0.000 claims description 4
- 230000002366 lipolytic effect Effects 0.000 claims description 4
- 210000002752 melanocyte Anatomy 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 231100000019 skin ulcer Toxicity 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 210000000434 stratum corneum Anatomy 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 3
- 229940123457 Free radical scavenger Drugs 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 238000004377 microelectronic Methods 0.000 claims description 3
- 230000000474 nursing effect Effects 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- 230000037307 sensitive skin Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 230000014616 translation Effects 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- 230000028937 DNA protection Effects 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 102000004237 Decorin Human genes 0.000 claims description 2
- 108090000738 Decorin Proteins 0.000 claims description 2
- 102000000541 Defensins Human genes 0.000 claims description 2
- 108010002069 Defensins Proteins 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 2
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 2
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 102000011990 Sirtuin Human genes 0.000 claims description 2
- 108050002485 Sirtuin Proteins 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 230000002293 adipogenic effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 238000003915 air pollution Methods 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000001166 anti-perspirative effect Effects 0.000 claims description 2
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 2
- 239000002488 antieczema agent Substances 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000003213 antiperspirant Substances 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001222 biopolymer Polymers 0.000 claims description 2
- 239000007844 bleaching agent Substances 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000019522 cellular metabolic process Effects 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 230000011382 collagen catabolic process Effects 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 239000007854 depigmenting agent Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000003602 elastase inhibitor Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000000417 fungicide Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 230000033444 hydroxylation Effects 0.000 claims description 2
- 238000005805 hydroxylation reaction Methods 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005645 linoleyl group Chemical group 0.000 claims description 2
- 239000007934 lip balm Substances 0.000 claims description 2
- 230000004130 lipolysis Effects 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 230000008099 melanin synthesis Effects 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 230000004118 muscle contraction Effects 0.000 claims description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000011814 protection agent Substances 0.000 claims description 2
- 238000001243 protein synthesis Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 229940125723 sedative agent Drugs 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 230000008728 vascular permeability Effects 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 230000002087 whitening effect Effects 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 241000021559 Dicerandra Species 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 235000012216 bentonite Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001288 lysyl group Chemical group 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 11
- 210000004877 mucosa Anatomy 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 114
- 239000011347 resin Substances 0.000 description 102
- 229920005989 resin Polymers 0.000 description 102
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 101
- 239000002904 solvent Substances 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- 125000001151 peptidyl group Chemical group 0.000 description 21
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 230000008878 coupling Effects 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 15
- 238000005859 coupling reaction Methods 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 235000010469 Glycine max Nutrition 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 12
- 244000068988 Glycine max Species 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 229910001873 dinitrogen Inorganic materials 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 244000081841 Malus domestica Species 0.000 description 9
- 235000011430 Malus pumila Nutrition 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 108010091748 peptide A Proteins 0.000 description 9
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical class C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 8
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- UPMGJEMWPQOACJ-UHFFFAOYSA-N 2-[4-[(2,4-dimethoxyphenyl)-(9h-fluoren-9-ylmethoxycarbonylamino)methyl]phenoxy]acetic acid Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(O)=O)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPMGJEMWPQOACJ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004890 Interleukin-8 Human genes 0.000 description 6
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 235000015103 Malus silvestris Nutrition 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 108010050808 Procollagen Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000010352 biotechnological method Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000008832 photodamage Effects 0.000 description 6
- 229960003471 retinol Drugs 0.000 description 6
- 239000011607 retinol Substances 0.000 description 6
- 235000020944 retinol Nutrition 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 230000037314 wound repair Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000004177 elastic tissue Anatomy 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000003344 environmental pollutant Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 4
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical class C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 4
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 4
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 4
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 4
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 4
- GKPMARPRXONRJX-BWJWTDLKSA-N (3s)-4-[[(2s,3s)-1-[[(2s)-1-amino-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-[[(2s)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid Chemical compound NC(=O)NCCC[C@@H](C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN GKPMARPRXONRJX-BWJWTDLKSA-N 0.000 description 4
- PMBXCGGQNSVESQ-UHFFFAOYSA-N 1-Hexanethiol Chemical group CCCCCCS PMBXCGGQNSVESQ-UHFFFAOYSA-N 0.000 description 4
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 4
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 4
- 108010087806 Carnosine Proteins 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 235000009496 Juglans regia Nutrition 0.000 description 4
- 240000007049 Juglans regia Species 0.000 description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940044199 carnosine Drugs 0.000 description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical group CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000006481 glucose medium Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000007665 sagging Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 3
- ITIMHIATVYROGF-XWUOBKMESA-N (3S)-3-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O ITIMHIATVYROGF-XWUOBKMESA-N 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 3
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 241000519590 Pseudoalteromonas Species 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000002288 golgi apparatus Anatomy 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 229960005337 lysine hydrochloride Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000005693 optoelectronics Effects 0.000 description 3
- 239000011772 phylloquinone Substances 0.000 description 3
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 235000019175 phylloquinone Nutrition 0.000 description 3
- 229960001898 phytomenadione Drugs 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 230000007838 tissue remodeling Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 2
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 2
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 2
- SAVSLMGBKQKUAV-JYJNAYRXSA-N (2s)-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-3-methyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound FC(F)(F)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 SAVSLMGBKQKUAV-JYJNAYRXSA-N 0.000 description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 2
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 2
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 2
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 240000007551 Boswellia serrata Species 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- 235000007575 Calluna vulgaris Nutrition 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000011922 Passiflora incarnata Nutrition 0.000 description 2
- 240000008440 Passiflora incarnata Species 0.000 description 2
- 235000010659 Phoenix dactylifera Nutrition 0.000 description 2
- 244000104275 Phoenix dactylifera Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 244000139010 Spilanthes oleracea Species 0.000 description 2
- 235000007892 Spilanthes oleracea Nutrition 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 240000000581 Triticum monococcum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 2
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000011138 biotechnological process Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical group CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 2
- 229960004135 idebenone Drugs 0.000 description 2
- 229960003696 ilomastat Drugs 0.000 description 2
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 2
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940033329 phytosphingosine Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical group CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- TVYSZBPKCYVUOM-ULQDDVLXSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-(hexanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O TVYSZBPKCYVUOM-ULQDDVLXSA-N 0.000 description 1
- KQEQPUBSXXOUGC-MLCQCVOFSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-acetylpyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(C)=O)C(O)=O KQEQPUBSXXOUGC-MLCQCVOFSA-N 0.000 description 1
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 description 1
- ZHUJMSMQIPIPTF-JMBSJVKXSA-N (2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-JMBSJVKXSA-N 0.000 description 1
- QNZANUZIBYJBIN-XSWJXKHESA-N (3s)-3-[[(2s)-2-acetamido-5-amino-5-oxopentanoyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNZANUZIBYJBIN-XSWJXKHESA-N 0.000 description 1
- KMACPCJUCHVVGP-FNRPHRCSSA-N (4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O KMACPCJUCHVVGP-FNRPHRCSSA-N 0.000 description 1
- QGGBBQJHVCVVKM-XOBYPWAZSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amin Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O QGGBBQJHVCVVKM-XOBYPWAZSA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- JPHRNERQGZBBPQ-UHFFFAOYSA-N 1-(7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-yl)hexadecan-1-one Chemical compound C1CC(C)(C)OC2=C1C=C(C(=O)CCCCCCCCCCCCCCC)C(OC)=C2 JPHRNERQGZBBPQ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- PSQFOYNNWBCJMY-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCOCCOCCO PSQFOYNNWBCJMY-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- VMTBVSIWYXRQED-UHFFFAOYSA-N 9h-xanthene-9-carbaldehyde Chemical compound C1=CC=C2C(C=O)C3=CC=CC=C3OC2=C1 VMTBVSIWYXRQED-UHFFFAOYSA-N 0.000 description 1
- 235000003934 Abelmoschus esculentus Nutrition 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000005274 Annona squamosa Nutrition 0.000 description 1
- 244000028821 Annona squamosa Species 0.000 description 1
- 241000001503 Anogeissus Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000238582 Artemia Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- NXTGWOGJZSSREB-HJXLNUONSA-N C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 Chemical compound C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 NXTGWOGJZSSREB-HJXLNUONSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229940127437 Chloride Channel Antagonists Drugs 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000005853 Cyperus esculentus Nutrition 0.000 description 1
- 244000285774 Cyperus esculentus Species 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 241000195633 Dunaliella salina Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 101000877447 Enterobacteria phage T4 Endonuclease V Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000195950 Equisetum arvense Species 0.000 description 1
- 239000005768 Equisetum arvense L. Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000017367 Guainella Nutrition 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 235000015265 Iris pallida Nutrition 0.000 description 1
- 240000004101 Iris pallida Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000226556 Leontopodium alpinum Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 244000217433 Melampodium divaricatum Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000978725 Mimosa tenuiflora Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- OLGWXCQXRSSQPO-MHARETSRSA-N P(1),P(4)-bis(5'-guanosyl) tetraphosphate Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=C(NC2=O)N)=C2N=C1 OLGWXCQXRSSQPO-MHARETSRSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 240000004064 Poterium sanguisorba Species 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 108010064622 Procollagen N-Endopeptidase Proteins 0.000 description 1
- 102000015339 Procollagen N-endopeptidase Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 235000000657 Rosa moschata Nutrition 0.000 description 1
- 244000018676 Rosa sp Species 0.000 description 1
- 244000297627 Senna alata Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 235000013474 Spilanthes acmella Nutrition 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 241001442052 Symphytum Species 0.000 description 1
- 241001424341 Tara spinosa Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000007251 Triticum monococcum Nutrition 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 241000894477 Ulva compressa Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940078033 acetyl octapeptide-3 Drugs 0.000 description 1
- 229940086540 acetyl tetrapeptide-9 Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- ZPFXAOWNKLFJDN-UHFFFAOYSA-N alverine Chemical compound C=1C=CC=CC=1CCCN(CC)CCCC1=CC=CC=C1 ZPFXAOWNKLFJDN-UHFFFAOYSA-N 0.000 description 1
- 229960000845 alverine Drugs 0.000 description 1
- 235000002783 ambrette Nutrition 0.000 description 1
- 244000096712 ambrette Species 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940011403 apple seed extract Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- ABRVDWASZFDIEH-UHFFFAOYSA-L calcium;2-hydroxy-4-methylsulfanylbutanoate Chemical compound [Ca+2].CSCCC(O)C([O-])=O.CSCCC(O)C([O-])=O ABRVDWASZFDIEH-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 description 1
- 229940017184 dimethylmethoxy chromanyl palmitate Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 229940064972 echinacea angustifolia extract Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940080813 hesperetin laurate Drugs 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940084105 peg-10 rapeseed sterol Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229940098780 tribehenin Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to peptides capable of promoting the proliferation of fibroblasts in the skin or mucous membranes, as well as cosmetic or pharmaceutical compositions containing these peptides and their use in the treatment or care of the skin or mucous membranes.
- the skin is the largest organ of the human body. It covers the body surface and plays an important barrier role for the body. It can resist mechanical damage, buffer external shocks, avoid damage to tissues and organs in the body, prevent the invasion of harmful substances from the outside, and resist oxidation and UV damage. It can also prevent the loss of various nutrients, water, and electrolytes in the body, and plays an important role in maintaining the stability of the internal environment of the human body.
- Skin consists of epidermis, dermis and subcutaneous tissue. The outermost layer is the epidermis, which is mainly composed of keratinocytes, melanocytes, and Langerhans cells.
- the dermis is located below the epidermis and contains dermal cells, collagen fibers, elastic fibers, matrix, hair, sebaceous glands, sweat glands, blood vessels, etc.
- the dermis is tightly connected to the epidermis by a basement membrane.
- Fibroblasts are large in size and diverse in shape, mostly protruding spindle-shaped or star-shaped flat structures.
- the cytoplasm contains rich and developed rough endoplasmic reticulum, Golgi apparatus, and free ribosomes, so it has a strong ability to synthesize and secrete proteins. Function, can secrete extracellular matrix components such as procollagen, fibronectin and collagenase.
- Fibroblasts use amino acids such as proline and lysine to synthesize proalpha polypeptide chains on the nucleosomes of the rough endoplasmic reticulum, and the polypeptide chains are transported to the Golgi apparatus to form procollagen molecules. ).
- Procollagen molecules are released extracellularly by exocytosis. Under the catalysis of procollagen peptidase, the tail segment of the pre-alpha polypeptide chain of the procollagen molecule is removed to become the procollagen molecule (tropocollagen).
- Procollagen molecules are arranged in parallel rows and combined into collagen fibrils with periodic horizontal striations. Collagen fibrils combine with each other to form collagen fibers. In addition to producing collagen fibers, fibroblasts can also produce elastic fibers.
- the main component of collagen fibers is type I collagen, which has strong tensile strength and gives skin toughness.
- Elastic fibers are composed of elastin and fibroin aggregates that give the skin its elasticity. Collagen fibers, elastic fibers, and extracellular matrix filled between fibers and cells form a support for the skin.
- the skin's morphology, physiology, and its mechanical properties undergo significant changes.
- the function of fibroblasts declines, collagen fibers and elastic fibers are damaged and broken, and the balance between the production and degradation of important biomolecules such as collagen in the skin is biased towards the degradation process with age, resulting in dermis Thinning and tissue destruction are progressive and cause relaxation of the dermis followed by wrinkling.
- Prolonged exposure to sunlight or environmental pollutants can accelerate the skin aging process.
- Ultraviolet rays can inhibit the synthesis of collagen and fibronectin in fibroblasts, and after ultraviolet radiation can cause high expression of matrix metalloproteinases (MMPs), causing serious damage to collagen in the dermis, resulting in the destruction of dermal integrity, skin strength and Decreased elasticity leads to accelerated aging of the skin.
- MMPs matrix metalloproteinases
- Non-pathogenic bacteria or opportunistic pathogenic bacteria will invade the skin, induce infection, and may even have a major impact on physical health. Therefore, accelerating the repair of skin wounds is of great significance in diseases with refractory wounds and postoperative repair.
- Wound repair is a precise, complex, time-phased dynamic process involving network regulation of various cells such as cell proliferation, migration, degradation of extracellular matrix, angiogenesis, and epithelial tissue remodeling.
- Fibroblasts are the main cells in wound repair. Mature fibroblasts are in a quiescent state, and their cell body volume is reduced, showing a long spindle shape, rough endoplasmic reticulum and Golgi apparatus are reduced, and mature fibroblasts are called fibroblasts. Fibroblasts and fibroblasts can transform into each other under certain conditions.
- fibroblasts Under the stimulation of trauma and other factors, some fibroblasts re-transform into immature fibroblasts, and their synthetic and secretory functions are restored accordingly, stimulating the generation of new extracellular matrix, and a large amount of extracellular matrix is combined with new capillaries to form granulation tissue to fill the defect organize.
- the proliferation and migration of fibroblasts are crucial to the formation of granulation tissue and the repair of wounds.
- fibroblasts are mainly involved in the proliferation phase and tissue remodeling phase of wound repair.
- fibroblasts proliferate, migrate and form granulation tissue in large numbers, which mainly play the role of resisting infection and filling wounds.
- fibroblasts play an important role in the process of skin aging and wound repair.
- the development of products that can promote the proliferation of fibroblasts can enhance the activity of fibroblasts and increase the content of collagen, elastin, glycosaminoglycans and other ingredients. Synthesize and secrete to compensate for the loss of extracellular matrix such as collagen and elastin with aging or exposure to sunlight and/or exposure to environmental pollutants, delay aging; fill the vacancy of necrotic tissue area after skin injury, and promote wound repair , is of great significance.
- the inventors of the present invention have surprisingly found that the proliferation and activity of fibroblasts can be regulated by certain synthetic peptides through a large number of experimental studies.
- the present invention aims to provide a peptide capable of promoting proliferation of fibroblasts in skin or mucous membranes.
- These peptides and cosmetic compositions or pharmaceutical compositions containing these peptides can improve or prevent the treatment or care of conditions, disorders or diseases of the skin or mucous membranes by promoting the proliferation of fibroblasts, thereby improving the skin barrier function or treating, preventing or treating Repair skin aging or photoaging, or for re-epithelialization or healing of skin or mucous membranes.
- the present invention provides a peptide represented by general formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt , characterized by:
- R is selected from: H, alkyl, alkenylalkyl, carboxyalkyl, esterylalkyl, alkylmercapto, carboxyalkylmercapto, or
- n is selected from: 1 or 2;
- R 1 is selected from: H or R 4 -CO-, wherein R 4 is selected from: substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl;
- R 3 is selected from: -NR 5 R 6 or -OR 5 , wherein each R 5 and R 6 are independently selected from each other: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl;
- the groups R1 and R3 are bound to the amino-terminus (N-terminus) and carboxy-terminus (C-terminus) of these peptide sequences, respectively.
- alkyl in the "alkyl”, “alkenylalkyl”, “carboxyalkyl”, “ester-based alkyl”, “alkylmercapto”, “carboxyalkylmercapto” refers to a group with 1-24 carbons Atom (optionally having 1-16 carbon atoms; optionally having 1-14 carbon atoms; optionally having 1-12 carbon atoms; optionally having 1, 2, 3, 4, 5, or 6 carbons atom) saturated aliphatic straight-chain or branched alkyl; optionally selected from: methyl, ethyl, isopropyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, decyl Base, dodecyl, tetradecyl, hexadecyl, octadecyl, 2-ethylhexyl, 2-methylbutyl, or 5-methylhexyl;
- alkenyl in the "alkenyl” and “alkenylalkyl” refers to having 2-24 carbon atoms (optionally having 2-16 carbon atoms; optionally having 2-14 carbon atoms; optionally having 2-12 carbon atoms, optionally having 2, 3, 4, 5, or 6 carbon atoms), straight-chain or branched alkenyl, said "alkenyl” having one or more carbon-carbon double bonds, Optionally have 1, 2 or 3 conjugated or non-conjugated carbon-carbon double bonds; said "alkenyl” is bonded to the rest of the molecule through a single bond; optionally selected from: vinyl, oil alkenyl, or linoleyl;
- substituted groups in groups of the present invention indicate that the specified group may be in one or more of the available positions, preferably in 1, 2, or 3 positions, more preferably in 1 or Two positions, still more preferably one position, are substituted with one or more substituents.
- R 2 is selected from: H, alkyl, alkenylalkyl, carboxyalkyl, esterylalkyl, alkylmercapto or carboxyalkylmercapto.
- R is selected from: H, acetyl, tert-butyryl, hexanoyl, 2-methylhexanoyl, capryl, decanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl acyl or linoleoyl.
- R is selected from H, acetyl, lauroyl, myristoyl or palmitoyl.
- R 1 is H, acetyl or palmitoyl.
- R 2 is selected from: H, -CH 3 , -CH 2 CH 3 , -CH 2 CH ⁇ CH 2 , -CH 2 COOH, -CH 2 COOC(CH 3 ) 3 , -S-CH 2 CH 3 , -S-(CH 2 ) 5 CH 3 , -S-CH 2 COOH or
- R 2 is selected from: H, -CH 3 , -CH 2 CH 3 , -CH 2 CH ⁇ CH 2 , -CH 2 COOH, -CH 2 COOC(CH 3 ) 3 , -S - CH2CH3 , -S-( CH2 ) 5CH3 or -S - CH2COOH .
- R and R are independently selected from each other: H, methyl , ethyl, hexyl, dodecyl or hexadecyl;
- R is H and R is selected from: H, methyl, ethyl, hexyl, dodecyl and hexadecyl;
- R 3 is -OH or -NH 2 .
- the peptide represented by formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, is selected from the following peptides (1)- (46):
- the peptide represented by formula (I) of the present invention may exist as a stereoisomer or a mixture of stereoisomers; for example, these amino acids contained therein may have the configuration of L-, D-, or independently of each other racemic.
- isomeric mixtures as well as racemic or diastereomeric mixtures, or pure diastereomers or enantiomers, depending on the number of asymmetric carbons and which isomers are present.
- Preferred structures of the peptides represented by formula (I) of the present invention are pure isomers, ie, enantiomers or diastereomers.
- -Phe- is mentioned in the present invention, it should be understood that -Phe- is selected from -L-Phe-, -D-Phe-, or a mixture of both, and is racemic or non-racemic.
- the preparation methods described in this document enable a person skilled in the art to obtain each stereoisomer of the peptides of the invention by selecting the amino acid with the correct configuration.
- compositions refers to a salt approved for use in animals, and more specifically in humans, including metal salts of peptides represented by formula (I),
- the metals include, but are not limited to: lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminum, etc.; including salts formed by the peptide represented by formula (I) and an organic base, and the organic base includes , but not limited to: ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine, etc.; including peptides and inorganic acids shown in formula (I) or salts of organic acids including, but not limited to: acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid acid, oleic acid, trifluoroacetic
- Peptides and Chemical Approaches to the Synthesis of Peptides and Proteins (1997), CRC, Boca Raton, FL, USA], synthesis in solution, solid phase synthesis, and synthesis in solution Combination of methods or enzymatic synthesis [Kullmann W. (Kullmann W.), "Proteases as catalysts for enzymic syntheses of opioid peptides” (1980), Biochemical Journal (J. Biol. Chem.), 255, 8234-8238].
- Peptides can also be prepared by biotechnological methods aimed at producing the desired sequence, or by controlled hydrolysis of proteins with animal, fungal, or preferably plant origin, which releases peptide fragments containing at least the desired sequence.
- a method for obtaining peptides of general formula (I) comprises the following steps:
- the C-terminus is bound to a solid support and the method is carried out on a solid phase, comprising combining an amino acid having a protected N-terminus and a free C-terminus with a free N-terminus and a Amino acid coupling of the C-terminus bound to the polymer carrier; elimination of the group protecting the N-terminus; and repeating this sequence as many times as required to thereby obtain a peptide of the desired length, followed by cleavage of the desired length from the original polymer carrier Synthetic peptides.
- the functional groups of the side chains of the amino acids remain fully protected with temporary or permanent protecting groups throughout the synthesis and can be deprotected simultaneously or orthogonally with the process of cleavage of the peptide from the polymeric support.
- solid phase synthesis can be performed by a convergent strategy in which dipeptides or tripeptides are coupled to a polymeric support or to dipeptides or amino acids previously bound to a polymeric support.
- Convergent synthesis strategies are well known to those skilled in the art and are described in Lloyd-Williams P., Albericio F. and Giralt E. "Convergent solid phase peptide synthesis", (1993), Tetrahedron 49:11065- 11133 in.
- the method may comprise the additional steps of deprotecting the N-terminus and C-terminus and/or cleaving the peptide from the polymer support in a non-determined order using standard conditions and methods known in the art, which may subsequently be modified. terminal functional groups.
- Optional modifications of the N-terminus and C-terminus can be carried out on the peptide of general formula (I) bound to a polymeric support, or after the peptide has been cleaved from the polymeric support.
- the peptides of the present invention can be administered in the form of compositions containing them by any means that cause contact between these peptides and the site of action in mammals (preferably, the site of action in humans) in order to promote fibroblasts. Proliferation, increase collagen production.
- another aspect of the present invention provides a cosmetic composition or a pharmaceutical composition, comprising an effective amount of the above-mentioned peptide of formula (I), or its stereoisomer, or a mixture of stereoisomers, or A cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, and at least one excipient or optionally a cosmetically or pharmaceutically acceptable adjuvant.
- These compositions can be prepared by conventional methods known to those skilled in the art ["Harry's Cosmetology", Seventh Edition, (1982), Wilkinson J.B. (Wilkinson J.B.), Moore R.J. ( Moore R.J., Longman House, Essex, UK].
- the adjuvant is selected from: a collagen synthesis stimulator, an agent that regulates the synthesis of PGC-1 ⁇ , an agent that regulates the activity of PPAR ⁇ , an agent that increases or decreases the triglyceride content of adipocytes, stimulates or delays the adipocyte Differentiation agents, lipolytic agents or lipolysis stimulating agents, lipolytic agents, adipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinases Inhibitors, melanin synthesis stimulators or inhibitors, whitening or depigmenting agents, hyperpigmentation agents, self-tanning agents, antiaging agents, NO-synthase inhibitors, 5 ⁇ -reductase inhibitors, lysyl hydroxylation Enzyme and/or prolyl hydroxylase inhibitors, antioxidants, free radical scavengers and/or anti-air pollution agents,
- these additional ingredients should not unacceptably alter the benefits of the peptides of the invention.
- the nature of these additional ingredients may be synthetic or natural such as plant extracts, or from a biotechnological process, or from a combination of a synthetic and a biotechnological process. Additional examples can be found in "CTFA International Cosmetic Ingredient Dictionary & Handbook", 12th Edition (2008).
- a biotechnological method is understood as any method for producing the active ingredient, or a part of the active ingredient, in an organism, or in a part of an organism.
- the above-mentioned cosmetic composition or pharmaceutical composition of the present invention may contain a cosmetically or pharmaceutically effective amount of at least one synthetic compound, plant extract, or product obtained by biotechnological methods, which is a collagen synthesis stimulating
- a cosmetically or pharmaceutically effective amount of at least one synthetic compound, plant extract, or product obtained by biotechnological methods which is a collagen synthesis stimulating
- ascorbic acid and its derivatives such as ascorbyl palmitate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate and ascorbyl ⁇ - and ⁇ -glucosides, retinol and retinol derivatives such as retinoic acid, retinol Xanthal, Retinyl Acetate or Retinyl Palmitate, Vegetable Extracts such as Aloe Vera and Centella Asiatica, Carnitine, Carnosine, Creatine, Asiatic Acid, Madecassic Acid, Centella Asiatica Grass glycosides, asiatica saponin, centella
- the aforementioned cosmetic or pharmaceutical composition of the present invention may contain a cosmetically or pharmaceutically effective amount of at least one synthetic compound, plant extract, or product obtained by biotechnological methods, which is an elastase-inhibiting Agents such as, without limitation, [INCI: Glycine Soja (Soybean) Protein], [INCI: Glycine Soja (Soybean) Protein, Oxidoreductase] or -Age [INCI: Hydrolyzed Rice Bran Hydrolyzed] sold by Pentapharm/DSM Glycerin, wild soybean (soybean) protein, oxidoreductase], Juvenesce sold by Coletica/Engelhard/BASF [INCI: Ethoxydiglycol and Caprylic Triglycerides, Retinol, Ursolic Acid, Vitamin K1, Ilox Ilomastat], MicromerolTM [INCI: Apple (Pyrus Malus) Extract], Heather Extract [INCI: Calluna Vulgaris Extract], [
- the above-mentioned cosmetic or pharmaceutical composition of the present invention may contain a cosmetically or pharmaceutically effective amount of at least one synthetic compound, plant extract, or product obtained by biotechnological methods, which is an active carbonyl species Substance scavengers, free radical scavengers and/or anti-glycation agents, such as and without limitation, carnosine and its derivatives, GHK [INCI: tripeptide-1] and its salts and/or derivatives, or sold by Lipotec [ INCI: hydrolyzed wheat protein, hydrolyzed soybean protein, tripeptide-1] or PreventheliaTM [INCI: diaminopropionyl tripeptide-33], etc.
- Substance scavengers, free radical scavengers and/or anti-glycation agents such as and without limitation, carnosine and its derivatives, GHK [INCI: tripeptide-1] and its salts and/or derivatives, or sold by Lipotec [ INCI: hydrolyzed wheat protein, hydro
- the above-mentioned cosmetic composition or pharmaceutical composition of the present invention may contain a cosmetically or pharmaceutically effective amount of at least one extract, which is an anti-wrinkle agent and/or an anti-aging agent, such as and not limited to, grape, Extracts of Rosa canina, Curcuma longa, Iris pallida, Theobroma cacao, Ginkgo biloba, Leontopodium Alpinum or Dunaliella salina, etc., or At least one synthetic compound or product which is an anti-wrinkle or anti-aging agent such as and without limitation, [INCI: Palmitoyl Pentapeptide-3], Matrixyl [INCI: Palmitoyl Tetrapeptide-7, Palmitoyl Oligopeptide], EssenskinTM [INCI: Calcium Hydroxymethionine], Renovage [INCI: Teprenone] or [INCI: Palmitoyl Oligopeptide], sold by Pentapharm/D SM [INCI: Five Peptide-3], Syn [INCI:
- the aforementioned cosmetic or pharmaceutical compositions of the present invention may contain a cosmetically or pharmaceutically effective amount of at least one synthetic compound, plant extract, or product obtained by biotechnological methods, which stimulates healing Agents, agents that assist healing, agents that stimulate re-epithelialization, and/or agents that assist re-epithelialization, such as, and not limited to, Centella asiatica extract, Rosa moschata extract, Echinacea angustifolia Echinacea angustifolia extract, Symphytum officinal extract, Equisetum arvense extract, Hypericum perforatum extract, Mimosa tenuiflora extract, Aloe vera vera) extract, Epithelizing sold by Provital [INCI: Calendula (Calendula officinalis), Hypericum, Matricaria (Chamomilla recutita), Rosemary (Rosmarinus officinalis)], LS9028 sold by Laboratories Serobi GmbH/Cognis [ INC
- the aforementioned cosmetic or pharmaceutical compositions of the present invention may contain or may be co-administered with analgesic and/or anti-inflammatory compounds in order to reduce swelling and swelling associated with sensitive skin and the healing process. irritation, or to treat overgrown scars or scars.
- analgesic and/or anti-inflammatory compounds in order to reduce swelling and swelling associated with sensitive skin and the healing process. irritation, or to treat overgrown scars or scars.
- emphasis may be placed on steroid-type compounds such as hydrocortisone, non-steroid-type compounds such as acetaminophen or acetylsalicylic acid, or natural extracts or essential oils with inherent analgesic and anti-inflammatory activities .
- the formulation of said cosmetic or pharmaceutical composition is selected from the group consisting of creams, oils, milks, balms, foams, lotions, gels, liniments, serums, soaps, shampoos, conditioners, serums , ointment, mousse, pomade, powder, stick, pen, spray, aerosol, capsule, tablet, granule, chewing gum, solution, suspension, emulsion, syrup, elixir, polysaccharide film, jelly or gelatin;
- the capsules include: soft capsules, hard capsules, optionally gelatin capsules;
- the tablet includes: sugar-coated tablet.
- compositions of the present invention may include transdermal enhancers that increase the absorption of the peptides of the present invention, such as and not limited to dimethylsulfoxide, dimethylacetamide, dimethylformamide, surfactants, nitrogen Ketone (1-dodecylazepan-2-one), alcohol, urea, ethoxydiglycol, acetone, propylene glycol or polyethylene glycol, etc.
- transdermal enhancers that increase the absorption of the peptides of the present invention, such as and not limited to dimethylsulfoxide, dimethylacetamide, dimethylformamide, surfactants, nitrogen Ketone (1-dodecylazepan-2-one), alcohol, urea, ethoxydiglycol, acetone, propylene glycol or polyethylene glycol, etc.
- the peptide represented by formula (I) of the present invention or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, or the Cosmetic or pharmaceutical compositions that can be prepared by iontophoresis, sonophoresis, electroporation, microelectropatch, mechanical compression, osmotic pressure gradient, dressing therapy, microinjection or needle-free injection with the aid of pressure (e.g. by Injections under oxygen pressure), or any combination thereof, are administered to the localized area to be treated in order to achieve greater penetration of the peptides of the invention.
- the area of administration will be determined by the nature of the condition, disorder and/or disease to be treated and/or cared for.
- the peptide represented by formula (I) according to the present invention may be incorporated into any form of functional food or fortified food, such as, and not limited to, dietary bars or compressed or non-compressed powders. These powders can be dissolved in water, juice, soda, dairy products, soy derivatives, or can be incorporated into meal bars.
- the peptides of the invention can be formulated with common excipients or adjuvants used in oral compositions or food supplements, such as and not limited to, fatty components, aqueous components, humectants, Preservatives, thickeners, flavorings, fragrances, antioxidants, or coloring agents.
- common excipients or adjuvants used in oral compositions or food supplements, such as and not limited to, fatty components, aqueous components, humectants, Preservatives, thickeners, flavorings, fragrances, antioxidants, or coloring agents.
- the peptides of the invention have variable solubility in water depending on the nature of their sequence or any possible modification in the N-terminus and/or C-terminus.
- the peptides of the present invention can thus be incorporated into compositions by aqueous solutions, and those that are insoluble in water can be dissolved in cosmetically or pharmaceutically acceptable conventional solvents such as and not limited to ethanol, propanol, isopropanol , propylene glycol, glycerin, butylene glycol, or polyethylene glycol, or any combination thereof.
- the cosmetically or pharmaceutically effective amount of the peptides of the invention to be administered, as well as their dosage, will depend on many factors, including age, the state of the patient, the severity of the condition or disease, the route and frequency of administration, and the nature of the peptide to be used. specific nature.
- Cosmetically or pharmaceutically effective amount means a non-toxic amount of one or more peptides of the invention which is sufficient to provide the desired effect.
- the peptides of the invention are used in the cosmetic or pharmaceutical compositions of the invention at a cosmetically or pharmaceutically effective concentration to obtain the desired effect; in a preferred form, at 0.00000001% ( By weight) and 20% by weight, preferably between 0.000001% by weight and 15% by weight, more preferably between 0.0001% by weight and 10% by weight by weight), and even more preferably between 0.0001% by weight and 5% by weight.
- a cosmetically or pharmaceutically acceptable delivery system or sustained release system in order to achieve better penetration of the active ingredient and/or to improve its pharmacokinetic and pharmacodynamic properties, which Comprising an effective amount of the peptide represented by the above-mentioned formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, or the above-mentioned cosmetic or pharmaceutical compositions;
- delivery system refers to a diluent, adjuvant, excipient or carrier with which the peptides of the invention are administered, selected from the group consisting of: water, oil or surfactants, including petroleum sources, animal sources, plant sources, or Those of synthetic origin, such as and not limited to peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glucosides, maltosides, fatty Alcohol, Nonoxynol, Poloxamer, Polyoxyethylene, Macrogol, Dextrose, Glycerin, Digitonin and the like.
- Those of ordinary skill in the art know the diluents that can be used in the different delivery systems in which the peptides of the invention can be administered.
- sustained release is used in the conventional sense to refer to a delivery system that provides a gradual release of the compound over a period of time, and preferably, but not necessarily, a relatively constant level of compound release over the entire period of time.
- Examples of delivery systems or sustained release systems are liposomes, oleosomes, nonionic surfactant liposomal vesicles, ethosomes, millimeter capsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges Cyclodextrins, lipid vesicles, micelles, millimeter spheres, microspheres, nanospheres, lipid spheres, microemulsions, nanoemulsions, millimeter particles, microparticles or nanoparticles.
- Preferred delivery systems or sustained release systems are liposomes and microemulsions, more preferably water-in-oil microemulsions with an internal structure of reverse micelles.
- Sustained release systems can be prepared by methods known in the art and can be administered, for example, by topical or transdermal administration, including adhesive patches, non-adherent patches, occlusive patches, and microelectronic patch; or by systemic administration such as and without limitation, oral or parenteral routes, including nasal, rectal, subcutaneous implantation or injection, or direct implantation or injection into specific body parts, and preferably should A relatively constant amount of these peptides of the invention is released.
- the amount of peptide contained in the sustained release system will depend, for example, on the site where the composition is to be administered, the release kinetics and duration of the peptide of the invention, and the condition, disorder and/or condition to be treated and/or cared for. the nature of the disease.
- Another aspect of the present invention provides a cosmetically or pharmaceutically acceptable solid organic polymer or solid inorganic support, which contains an effective amount of the peptide represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a cosmetic or pharmaceutical composition as described above; selected from, but not limited to: talc, bentonite, dioxide Silicon, starch, or maltodextrin, etc.
- Another aspect of the present invention provides a cosmetic product comprising an effective amount of the above-mentioned peptide represented by formula (I), or its stereoisomer, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof , or a pharmaceutically acceptable salt thereof, or the aforementioned cosmetic or pharmaceutical composition;
- the cosmetic is selected from the group consisting of: concealer, foundation, makeup remover, makeup remover milk, eye shadow, lip stick, lip gloss, lip balm or lip powder.
- Another aspect of the present invention provides a fabric, non-woven fabric or medical device, which comprises an effective amount of the above-mentioned peptide represented by formula (I), or a stereoisomer or a mixture of stereoisomers thereof, or A cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the aforementioned cosmetic or pharmaceutical composition.
- the peptides of the invention are released due to biodegradation of the fabric or non-woven fabric or the anchoring system of the medical device or by friction with the body, by body moisture, by the pH of the skin or by body temperature.
- woven and nonwoven fabrics can be used to make clothes that come into direct contact with the body.
- fabrics, nonwovens, clothing, medical devices and means of immobilizing peptides to them include the above-mentioned delivery systems and/or sustained release systems, which can be found in the literature and are known in the prior art [Schaab C.K. (1986 ) "Impregnating Fabrics With Microcapsules (using microcapsules to impregnate fabrics)", HAPPI May 1986; Nelson G. (2002) “Application of microencapsulation in textiles (microencapsulation in textiles)” Int.J.Pharm.242: 5562; “Biofunctional Textiles and the Skin” (2006) Curr.Probl.Dermatol.v.33, edited by Hipler U.C. and Elsner P. S.
- Preferred fabrics, nonwovens, clothing or medical devices are bandages, gauze, t-shirts, socks, pantyhose, underwear, girdles, gloves, diapers, sanitary napkins, dressings, bedspreads, wipes, adhesive patches patch, non-adhesive patch, occlusive patch, microelectronic patch or mask.
- Another aspect of the present invention provides a peptide represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable Acceptable salts, or cosmetic or pharmaceutical compositions described above, or cosmetically or pharmaceutically acceptable delivery systems or sustained release systems described above, or cosmetically or pharmaceutically acceptable solid organic polymers or solid inorganic supports described above , or the above-mentioned cosmetics, or the use of the above-mentioned fabric, non-woven fabric or medical device in the preparation of a cosmetic or pharmaceutical composition for the treatment or care of the skin or mucous membranes.
- Another aspect of the present invention provides a peptide represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable Acceptable salts, or cosmetic or pharmaceutical compositions described above, or cosmetically or pharmaceutically acceptable delivery systems or sustained release systems described above, or cosmetically or pharmaceutically acceptable solid organic polymers or solid inorganic supports described above , or the above-mentioned cosmetics, or the above-mentioned fabrics, non-woven fabrics or medical devices in the preparation of cosmetic compositions or pharmaceutical compositions for treating or nursing body surface wounds, burns, skin ulcers, reducing scar generation, or accelerating scar repair the use of.
- Another aspect of the present invention provides a peptide represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable Acceptable salts, or cosmetic or pharmaceutical compositions described above, or cosmetically or pharmaceutically acceptable delivery systems or sustained release systems described above, or cosmetically or pharmaceutically acceptable solid organic polymers or solid inorganic supports described above , or the above-mentioned cosmetics, or the above-mentioned fabrics, non-woven fabrics or medical devices in the preparation for promoting fibroblast proliferation, increasing collagen production, for improving skin barrier function, or for re-epithelialization of skin or mucous membranes or Use in a healing cosmetic or pharmaceutical composition.
- One aspect of the present invention provides a peptide represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable or the above-mentioned cosmetic or pharmaceutical composition, or the above-mentioned cosmetically or pharmaceutically acceptable delivery system or sustained-release system, or the above-mentioned cosmetically or pharmaceutically acceptable solid organic polymer or solid inorganic support, Or the above-mentioned cosmetics, or the use of the above-mentioned fabrics, non-woven fabrics or medical devices in the preparation of cosmetic compositions or pharmaceutical compositions for treating, preventing or repairing skin aging or photoaging.
- the treatment, prevention or repair of skin aging or photoaging is the reduction, prevention or treatment of facial wrinkles.
- Another aspect of the present invention provides a method for treating or caring for skin or mucous membranes, the method comprising administering a cosmetically or pharmaceutically effective amount of the above-mentioned peptide represented by formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the aforementioned cosmetic or pharmaceutical composition.
- Another aspect of the present invention provides a method for treating or nursing body surface wounds, burns, skin ulcers, reducing scar production, and accelerating scar repair, the method comprising administering a cosmetically or pharmaceutically effective amount of the above-mentioned formula (I ), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the aforementioned cosmetic or pharmaceutical composition.
- a method for promoting fibroblast proliferation, increasing collagen production, for improving skin barrier function, or for re-epithelialization or healing of skin and/or mucous membranes comprising administering A cosmetically or pharmaceutically effective amount of the peptide represented by the above formula (I), or its stereoisomer, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, or the aforementioned cosmetic or pharmaceutical compositions.
- Another aspect of the present invention provides a method for treating, preventing or repairing skin aging or photoaging, the method comprising administering a cosmetically or pharmaceutically effective amount of the above-mentioned peptide represented by formula (I), or its stereo isomers, or mixtures of stereoisomers, or cosmetically acceptable salts thereof, or pharmaceutically acceptable salts thereof, or the aforementioned cosmetic or pharmaceutical compositions.
- the treatment, prevention or repair of skin aging or photoaging is the reduction, prevention or treatment of facial wrinkles.
- compositions of cosmetic or pharmaceutical compositions may be applied to the skin and/or mucous membranes, or administered orally or parenterally as required for the treatment and/or care of a condition, disorder and/or disease.
- the frequency of administration or dosing can vary widely depending on the needs of each subject, with suggested administration or dosing ranging from 1 time per month to 10 times per day, preferably from 1 time per week to 4 times per day, More preferably from 3 times a week to 3 times a day, even more preferably 1 or 2 times a day.
- the term “skin” is understood to mean the layers that make it up, from the uppermost layer or stratum corneum to the lowermost layer or subcutaneous tissue, both inclusive. These layers are composed of different types of cells, such as keratinocytes, fibroblasts, melanocytes, and/or adipocytes, among others. In the present invention, the term “skin” includes the scalp.
- treatment refers to the administration of the peptides according to the present invention to alleviate or eliminate a disease or condition, or to reduce or eliminate one or more symptoms associated with such a disease or condition.
- treatment also encompasses the ability to alleviate or eliminate the physiological consequences of the disease or disorder.
- the term "care” includes the prevention of diseases and/or conditions.
- prevention refers to the ability of the peptides of the invention to prevent, delay, or impede the onset or development of a disease or condition before it occurs.
- aging refers to the changes the skin undergoes as it ages (natural aging), or through exposure to sunlight (photoaging) or exposure to environmental pollutants such as chemical dirt or pollutants, tobacco smoke, etc. changes, and includes all externally visible and/or perceptible changes by touch, such as and not limited to: the development of discontinuities in the skin (such as wrinkles, fine lines, expression lines, stretch marks, striae, furrows wrinkles, unevenness or roughness, increased pore size, loss of moisture, loss of elasticity, loss of firmness, loss of smoothness, loss of ability to recover from deformation, loss of resilience), sagging of the skin (such as sagging cheeks, bags under the eyes, or double chin, etc.), changes in skin color (such as scarring, redness, bags under the eyes, or areas of hyperpigmentation such as age spots or freckles), abnormal differentiation, hyperkeratinization, elastosis, keratosis, hair loss, orange Dermoid skin, loss of collagen structure, and other histologic
- photoaging refers to premature aging of the skin due to long-term exposure of the skin to ultraviolet radiation, which exhibits the same physiological characteristics as natural aging, such as and not limited to: sagging, sagging, color changes or hyperpigmentation Regular, abnormal and/or hyperkeratosis.
- Ala represents NH2 -CH( CH3 )-COOH
- Ala- represents NH2 -CH( CH3 )-CO-
- -Ala represents -NH-CH( CH3 )-COOH
- -Ala- Represents -NH-CH(CH 3 )-CO-.
- Ac- is used in the present invention to denote the acetyl group (CH 3 -CO-), and the abbreviation “Palm-” is used to denote the palmitoyl group (CH 3 -(CH 2 ) 14 -CO-).
- the peptide described in the present invention is obtained by artificial design, is easy to synthesize, can promote the proliferation of fibroblasts, improve the skin barrier function, is beneficial to promote wound healing, treat or care for body surface wounds, burns, skin ulcers, reduce scar generation, and accelerate scarring Restorative, and also useful for treating, preventing and/or repairing skin aging and/or photoaging.
- Fig. 4 is a graph showing the results of the scratch experiment on HaCaT cells.
- Fig. 5 is a graph showing the repairing effect of peptide (1) to peptide (5) on light-damaged HaCaT cells.
- Fig. 6 is a graph showing the repairing effect of peptide (1) and peptide (2) on photodamaged NIH3T3 cells.
- Wang Resin Wang resin; DMF: N,N-dimethylformamide; DCM: dichloromethane; DIC: diisopropylcarbodiimide; Ac 2 O: acetic anhydride; DIPEA: diisopropylethylamine ; Fmoc: 9-fluorenylmethoxycarbonyl; piperidine: piperidine; HOBt: 1-hydroxybenzotriazole; TFA: trifluoroacetic acid; TIS: triisopropylsilane; EDT: 1,2-ethanedisulfide Alcohol; DMSO: Dimethyl Sulfoxide; Ac: Acetyl; Palm: Palmitoyl; Ala: Alanine; Pro: Proline; Phe: Phenylalanine; Arg: Arginine; Met: Methionine acid; Gly: glycine; Ile: isoleucine; Cys: cysteine; Thr: threonine; Asn: asparagine; Pb
- the swollen resin was de-Fmoc twice with 500ml 20% piperidine/DMF, the first reaction was 5 minutes, the second reaction was 8 minutes, and the solvent was drained for 3 minutes. Wash the resin 7-8 times with DMF, and remove the solvent.
- the degree of substitution of the resin was detected to be 0.5, and the calculated synthesis scale was 24.9 mmol.
- the N-terminal Fmoc group was deprotected, and 24.74 g of activated Fmoc-Thr(tBu)-OH (62.25 mmol; 2.5 equiv.) Coupled to the peptidyl resin, the reaction continued for 2h. The resins were then washed and the deprotection treatment of the Fmoc group repeated for coupling of the next amino acid.
- the N-terminal Fmoc group was deprotected and 32.37 g of activated Fmoc-Met-OH (87.15 mmol; 3.5 equiv.) was coupled to On the peptidyl resin, the reaction was continued for 2h. The resins were then washed and the deprotection treatment of the Fmoc group repeated for coupling of the next amino acid.
- the resin was washed with DMF, 100 ml each time, the resin and the solvent were uniformly mixed, stirred for 2 minutes, and the solvent was drained. The resin was washed several times with DMF until the solvent filtered out with suction was clear and transparent.
- Fmoc-Linker-Amide Resin was de-Fmoc twice with 500ml 20% piperidine/DMF, the first reaction was 5 minutes, the second reaction was 8 minutes, and the solvent was drained for 3 minutes. 500ml DMF wash resin 4 times, 500ml DCM wash resin 2 times. Aspirate off the solvent.
- the N-terminal Fmoc group was deprotected and 34.78 g of activated Fmoc-Thr(tBu)-OH (87.5 mmol) was coupled to the peptidyl group in the presence of 14 g HOBt and 20 ml DIC using DMF as solvent On the resin, the reaction was continued for 2h. The resins were then washed and the deprotection treatment of the Fmoc group repeated for coupling of the next amino acid.
- the resin was washed 4 times with 600 ml DMF for 2 min each, 2 times with 500 ml DCM and the solvent was aspirated off.
- the N-terminal Fmoc protecting group was removed.
- the R 1 palmitoyl group was introduced onto the peptidyl resin obtained in Example 3.
- the R 1 acetyl group was introduced onto the peptidyl resin obtained in Example 3.
- the peptidyl resins obtained in Examples 3, 4, and 5 were shrunk three times with 500 ml, 300 ml, and 200 ml of methanol. Vacuum dry.
- Example 6 The crude peptide obtained in Example 6 was dissolved with methanol and water, and filtered with a filter membrane with a pore size of 0.45 ⁇ m.
- Mobile phase A pure acetonitrile
- mobile phase B 0.1% acetic acid aqueous solution
- the filtered sample was injected and purified, the fractions were collected, concentrated and freeze-dried to obtain the following peptides with a purity of over 90%:
- Palm-Ala-Pro-Phe-Arg-Met-Gly-Ile-Cys-Thr-Thr-Asn-NH 2 namely peptide (9);
- Example 7 The peptide obtained in Example 7 was oxidized.
- Example 7 The peptide obtained in Example 7 was added to a 250ml pear-shaped bottle, dissolved in 80ml of purified water, 8g of guanidine hydrochloride and 20ml of DMSO were added, stirred for 30h with the open mouth, and the reaction process was monitored by HPLC. After oxidation, add 4 ml of acetic acid to dissolve the precipitate, and vacuum filter it with a 0.22 ⁇ m filter membrane.
- Example 8 The filtrate obtained in Example 8 was purified by high performance liquid chromatography.
- Mobile phase A pure acetonitrile
- mobile phase B 0.1% acetic acid aqueous solution
- the mercapto group of the side chain of Cys8 of the peptide obtained in Example 7 was modified with mercaptoethane.
- Mobile phase A pure acetonitrile
- mobile phase B 0.1% acetic acid aqueous solution
- the swollen resin was de-Fmoc twice with 500ml 20% piperidine/DMF, the first reaction was 5 minutes, the second reaction was 8 minutes, and the solvent was drained for 3 minutes. Wash the resin 7-8 times with DMF, and remove the solvent.
- the degree of substitution of the resin was detected to be 0.5, and the calculated synthesis scale was 24.9 mmol.
- the N-terminal Fmoc group was deprotected, and 24.74 g of activated Fmoc-Thr(tBu)-OH (62.25 mmol; 2.5 eq. ) was coupled to the peptidyl resin, and the reaction was continued for 2h. The resins were then washed and the deprotection treatment of the Fmoc group repeated for coupling of the next amino acid.
- the N-terminal Fmoc group was deprotected and 32.37 g of activated Fmoc-Met-OH (87.15 mmol; 3.5 equivalents) were coupled to On the peptidyl resin, the reaction was continued for 2h. The resins were then washed and the deprotection treatment of the Fmoc group repeated for coupling of the next amino acid.
- the resin was washed with DMF, 100 ml each time, the resin and the solvent were uniformly mixed, stirred for 2 minutes, and the solvent was drained. The resin was washed several times with DMF until the solvent filtered out with suction was clear and transparent.
- Fmoc-Linker-Amide Resin was de-Fmoc twice with 500ml 20% piperidine/DMF, the first reaction was 5 minutes, the second reaction was 8 minutes, and the solvent was drained for 3 minutes. 500ml DMF wash resin 4 times, 500ml DCM wash resin 2 times. Aspirate off the solvent.
- the N-terminal Fmoc group was deprotected and 34.78 g of activated Fmoc-Thr(tBu)-OH (87.5 mmol) was coupled to the peptide in the presence of 14 g HOBt and 20 ml DIC using DMF as solvent On the base resin, the reaction was continued for 2h. The resins were then washed and the deprotection treatment of the Fmoc group repeated for coupling of the next amino acid.
- the resin was washed 4 times with 600 ml DMF for 2 min each, 2 times with 500 ml DCM and the solvent was aspirated off.
- the N-terminal Fmoc protecting group was removed.
- the R 1 palmitoyl group was introduced onto the peptidyl resin obtained in Example 18.
- the R 1 acetyl group was introduced onto the peptidyl resin obtained in Example 18.
- the peptidyl resins obtained in Examples 18, 19 and 20 were cleaved from the polymer support.
- the peptidyl resins obtained in Examples 18, 19 and 20 were shrunk three times with 500 ml, 300 ml, and 200 ml of methanol. Vacuum dry.
- Example 21 The crude peptide obtained in Example 21 was dissolved with methanol and water, and filtered through a filter membrane with a pore size of 0.45 ⁇ m.
- Mobile phase A pure acetonitrile
- mobile phase B 0.1% acetic acid aqueous solution
- the filtered sample was injected and purified, the fractions were collected, concentrated and freeze-dried to obtain the following peptides with a purity of over 90%:
- PBS Phosphate buffered saline
- MTT thiazolium blue
- DMSO dimethylsulfoxide
- DMEM high glucose medium
- fetal bovine serum Gibco
- Microplate reader (MD, USA), CO 2 incubator (Shanghai Yiheng), ultra-clean bench (Suzhou Purification), biological inverted microscope (Chongqing Optoelectronics).
- HaCaT Human keratinocytes
- NIH3T3 mouse skin fibroblasts
- Administration groups peptide (1), peptide (2), peptide (3), peptide (4), peptide (5), the concentrations were 12.5ppm, 25ppm, 50ppm, 100ppm respectively.
- Control group PBS blank control.
- MTT method is a method to detect cell survival and growth.
- the measured OD value is directly proportional to cell activity. The larger the OD value, the higher the cell activity.
- PBS Phosphate buffered saline
- MTT thiazolium blue
- DMSO dimethylsulfoxide
- DMEM high glucose medium
- fetal bovine serum Gibco
- Microplate reader (MD, USA), CO 2 incubator (Shanghai Yiheng), ultra-clean bench (Suzhou Purification), biological inverted microscope (Chongqing Optoelectronics).
- HaCaT Human keratinocytes
- Administration group peptide (1), peptide (2), the concentrations were 12.5ppm, 25ppm, 50ppm, 100ppm respectively. Dissolve with PBS solution.
- Control group PBS blank control.
- the cryopreserved HaCaT human cuticle cells were cultured, subcultured at a ratio of 1:2 to about 5 passages, and the cells with better growth were selected as the experimental objects.
- the sample to be tested was added to a 96-well plate at a rate of 20 ⁇ L/well, and dried overnight in a constant temperature oven at 37°C.
- On the second day after digesting the well-growing HaCaT cells, seed the plate at a density of 10,000 HaCaT cells/well, supplement the medium to 200 ⁇ L, and incubate for 3 hours at 37°C and 5% CO 2 incubator. After the culture is over, take out the culture plate and continue to replenish the culture medium until the liquid level just overflows, and seal it with a parafilm to ensure that there are no air bubbles. Turn over for 20 minutes under the action of a three-dimensional force.
- the original medium was discarded, and 90 ⁇ L of fresh medium and 10 ⁇ L of 5 mg/mL MTT were added to each well, and placed in a 37° C., 5% CO 2 incubator for 3 h. Discard the solution and add 150 ⁇ L of DMSO. Set the detection wavelength to 490nm, the reference wavelength to 630nm, and use a microplate reader to read the OD value.
- HaCaT cells By selecting HaCaT cells, plate them in a drug-coated 96-well plate, and after incubation and a period of three-dimensional force, the cells with strong adhesion can be maintained on the 96-well plate.
- MTT quantitative analysis on the live cells on the plate, That is, the effect of the drug on cell adhesion can be evaluated to determine whether the peptide of the present invention can improve cell elasticity. After three-dimensional force action, the more living cells remained on the 96-well plate, the greater the measured OD value, indicating the stronger the adhesion of the cells.
- PBS Phosphate buffered saline
- DMEM high glucose medium
- fetal bovine serum Gibco
- HaCaT Human keratinocytes
- Administration group 100 ppm of peptide (1), 100 ppm of peptide (2), 50 U/mL of epidermal growth factor (EGF).
- EGF epidermal growth factor
- Control group PBS blank control.
- the cryopreserved HaCaT cells were cultured, subcultured to about 5 passages according to the ratio of 1:2, and the cells with better growth were selected as the experimental objects.
- Cells were seeded in a 12-well plate at a density of 200,000 cells/well, with 2 mL of cell suspension in each well. After the cells adhered to the wall, the medium was replaced with 0.5% to 1% fetal bovine serum to maintain the cells for 24 hours to synchronize them. change. Scratch with a sterilized pipette tip, wash off the dropped cells with PBS, add the sample to be tested, continue to incubate in a 37°C, 5% CO 2 incubator, and place it under an optical microscope after 24 hours to analyze the wound healing area.
- the cell scratch migration test can reflect the proliferation and repair ability of the cells.
- the results are shown in Figure 4.
- the cell scratches in the normal control group are still obvious, and the scratch spacing is normal; compared with the control group, the cell proliferation and migration in the EGF positive group is obvious. , the spacing was significantly shortened; while the scratch spacing of peptide (1) and peptide (2) was shorter than that of the normal control group, and cell migration tracks appeared, it can be known that the peptide of the present invention can promote HaCaT human keratin formation Cell proliferation and migration, has the effect of skin repair.
- PBS Phosphate buffered saline
- MTT thiazolium blue
- DMSO dimethylsulfoxide
- DMEM high glucose medium
- fetal bovine serum Gibco
- Microplate reader (MD, USA), CO 2 incubator (Shanghai Yiheng), ultra-clean bench (Suzhou Purification), biological inverted microscope (Chongqing Optoelectronics).
- HaCaT Human keratinocytes
- NIH3T3 mouse skin fibroblasts
- the concentrations of peptide (1), peptide (2), peptide (3), peptide (4), and peptide (5) were 12.5 ppm, 25 ppm, 50 ppm, and 100 ppm, respectively.
- peptide (1) can significantly increase cell activity at 50 and 100ppm; peptide (2) can significantly increase NIH3T3 cell activity at each dose of 12.5ppm-100ppm. This shows that both peptide (1) and peptide (2) can repair photodamaged NIH3T3 cells within a certain concentration range, improve their activity, and have good skin repair ability.
- Microplate reader (MD, USA), CO 2 incubator (Shanghai Yiheng), ultra-clean bench (Suzhou Purification).
- Peptide (2) tested at a concentration of 100 ppm.
- Operate according to the ELISA operating instructions move all reagents to room temperature and equilibrate for at least 30 minutes, prepare reagents according to the instructions, and set aside. Set up wells for standard products and wells for samples to be tested, add 100 ⁇ L of standard products or samples to be tested in each well, shake gently, cover with plate stickers, and incubate at 37°C for 2 hours. 4 replicate wells were set up for each sample. Discard the liquid, spin dry, and wash the plate 5 times. Add 100 ⁇ L of biotin-labeled antibody working solution to each well, cover with a new plate sticker, and incubate at 37°C for 1 h.
- Inflammatory factors such as TNF- ⁇ , IL-6 and IL-8 can cause excessive immune response of the body, leading to skin ulceration, redness and swelling, etc. Therefore, inhibiting inflammatory factors such as TNF- ⁇ , IL-6 and IL-8 can achieve Anti-inflammatory repair effect.
- the inflammation model was established by stimulating RAW264.7 cells with 200ng/mL LPS, and the anti-inflammatory repairing effect of the peptide of the present invention was explored.
- HPLC chromatographic separation conditions are as follows:
- test solution Take an appropriate amount of this product and add water to dissolve and dilute to make a solution containing 1 mg per 1 ml.
- Dipalmitoylphosphatidylcholine was weighed out and dissolved in chloroform. The solvent was evaporated under vacuum until a thin layer of phospholipids was obtained, which was hydrated by treatment with an aqueous peptide solution of the desired concentration at 55°C to give multilamellar liposomes.
- the multi-lamellar liposomes are homogenized under high pressure to obtain smaller and uniform single-lamellar liposomes.
- phase B According to the prescribed dosage, weigh the ingredients of Phase B and add them to the container. Next, add phase D to phase B and homogenize with continuous stirring. Phase A is then added to the mixture. Finally, phase C is added to obtain a microemulsion composition containing peptide (2).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
时间(min) | 流速(ml/min) | A% | B% |
0 | 40 | 10 | 90 |
3 | 40 | 12 | 88 |
63 | 40 | 37 | 63 |
64 | 40 | 10 | 90 |
75 | 40 | 10 | 90 |
时间(min) | 流速(ml/min) | A% | B% |
0 | 40 | 8 | 92 |
5 | 40 | 8 | 92 |
50 | 40 | 53 | 47 |
53 | 40 | 8 | 92 |
65 | 40 | 8 | 92 |
时间(min) | 流速(ml/min) | A% | B% |
0 | 40 | 11 | 89 |
48 | 40 | 35 | 65 |
56 | 40 | 38 | 62 |
59 | 40 | 48 | 52 |
60 | 40 | 80 | 20 |
70 | 40 | 80 | 20 |
时间(min) | 流速(ml/min) | A% | B% |
0 | 40 | 10 | 90 |
4 | 40 | 12 | 88 |
64 | 40 | 32 | 68 |
65 | 40 | 10 | 90 |
75 | 40 | 10 | 90 |
试验条件 | 参比肽A水溶液(纯度) | 肽(1)水溶液(纯度) | 肽(2)水溶液(纯度) |
溶液0天 | 88.030% | 98.443% | 99.291% |
常温8天 | 80.880% | 98.362% | 99.122% |
常温18天 | 72.693% | 96.703% | 98.045% |
样品编号 | 0天(纯度) | 高湿10天(纯度) |
肽(3) | 97.605% | 96.251% |
肽(4) | 96.017% | 93.962% |
肽(5) | 97.482% | 94.603% |
肽(6) | 96.235% | 95.719% |
肽(7) | 98.541% | 97.863% |
Claims (18)
- 式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,式(I)中,R 2选自:H、烷基、烯基烷基、羧基烷基、酯基烷基、烷基巯基、羧烷基巯基、或式(I)和式(i)中,n选自:1或2;R 1选自:H或R 4-CO-,其中R 4选自:取代的或未取代的烷基、取代的或未取代的烯基;R 3选自:-NR 5R 6或-OR 5,其中各个R 5和R 6彼此独立地选自:H、取代的或未取代的烷基、取代的或未取代的烯基;所述“烷基”、“烯基烷基”、“羧基烷基”、“酯基烷基”“烷基巯基”、“羧烷基巯基”中的烷基是指具有1-24个碳原子(可选具有1-16个碳原子;可选具有1-14个碳原子;可选具有1-12个碳原子;可选具有1、2、3、4、5、或6个的碳原子)的饱和脂肪族直链或支链的烷基;可选选自:甲基、乙基、异丙基、异丁基、叔丁基、戊基、己基、庚基、辛基、癸基、十二烷基、十四烷基、十六烷基、十八烷基、2-乙基己基、2-甲基丁基、或5-甲基己基;所述“烯基”、“烯基烷基”中的烯基是指具有2-24个碳原子(可选具有2-16个碳原子;可选具有2-14个碳原子;可选具有2-12个碳原子、可选具有2、3、4、5、或6个碳原 子)的直链或支链烯基,所述“烯基”具有一个或多个碳-碳双键,可选具有1、2或3个共轭或非共轭的碳-碳双键;所述“烯基”是通过一个单键而结合至分子的其余部分;可选选自:乙烯基、油烯基、或亚油烯基;所述“酯基烷基”中的酯基为R(C=O)OR′基团,其中,R、R′各自独立地为单键、烷基或亚烷基;可选地,所述“取代的烷基”、“取代的烯基”中的取代基选自C 1-C 4烷基;羟基;C 1-C 4烷氧基;氨基;C 1-C 4氨基烷基;C 1-C 4羰氧基;C 1-C 4氧基羰基;卤素(如氟、氯、溴、以及碘);氰基;硝基;叠氮化物;C 1-C 4烷基磺酰基;硫醇;C 1-C 4烷硫基;C 6-C 30芳氧基如苯氧基;-NR b(C=NR b)NR bR c,其中R b和R c是独立地选自:H、C 1-C 4烷基、C 2-C 4烯基、C 2-C 4炔基、C 3-C 10环烷基、C 6-C 18芳基、C 7-C 17芳烷基、具有三至十元的杂环基、或氨基的保护基。
- 根据权利要求1所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,其特征在于,式(I)中,当n为2时,R 2选自:H、烷基、烯基烷基、羧基烷基、酯基烷基、烷基巯基或羧烷基巯基。
- 根据权利要求1或2所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,其特征在于,R 1选自:H、乙酰基、叔-丁酰基、己酰基、2-甲基己酰基、辛酰基、癸酰基、月桂酰基、肉豆蔻酰基、棕榈酰基、硬脂酰基、油酰基或亚油酰基;可选地,R 1选自H、乙酰基、月桂酰基、肉豆蔻酰基或棕榈酰基;可选地,R 1是H、乙酰基或棕榈酰基。
- 根据权利要求1或2所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,其特征在于,R 5、R 6彼此独立地选自:H、甲基、乙基、己基、十二烷基或十六烷基;可选地,R 5是H并且R 6选自:H、甲基、乙基、己基、十二烷基或十六烷基;可选地,R 3是-OH或-NH 2。
- 根据权利要求1-5任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,其特征在于,选自下列肽(1)-(46):(2)H-Ala-Pro-Phe-Arg-Met-Gly-Ile-Met-Thr-Thr-Asn-OH;(8)Palm-Ala-Pro-Phe-Arg-Met-Gly-Ile-Cys-Thr-Thr-Asn-OH;(9)Palm-Ala-Pro-Phe-Arg-Met-Gly-Ile-Cys-Thr-Thr-Asn-NH 2;(10)Ac-Ala-Pro-Phe-Arg-Met-Gly-Ile-Cys-Thr-Thr-Asn-OH;(11)Ac-Ala-Pro-Phe-Arg-Met-Gly-Ile-Cys-Thr-Thr-Asn-NH 2;(42)H-Ala-Pro-Phe-Arg-Met-Gly-Ile-Met-Thr-Thr-Asn-NH 2;(43)Palm-Ala-Pro-Phe-Arg-Met-Gly-Ile-Met-Thr-Thr-Asn-OH;(44)Palm-Ala-Pro-Phe-Arg-Met-Gly-Ile-Met-Thr-Thr-Asn-NH 2;(45)Ac-Ala-Pro-Phe-Arg-Met-Gly-Ile-Met-Thr-Thr-Asn-OH;(46)Ac-Ala-Pro-Phe-Arg-Met-Gly-Ile-Met-Thr-Thr-Asn-NH 2。
- 根据权利要求1-6任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,其特征在于,所述美容上可接受的盐或药学上可接受的盐包括式(I)所示的肽的金属盐,所述金属包括:锂、钠、钾、钙、镁、锰、铜、锌或铝;可选地,所述美容上可接受的盐或药学上可接受的盐包括式(I)所示的肽与有机碱形成的盐,所述有机碱包括:乙胺、二乙胺、乙二胺、乙醇胺、二乙醇胺、精氨酸、赖氨酸、组氨酸或哌嗪;可选地,所述美容上可接受的盐或药学上可接受的盐包括式(I)所示的肽与无机酸或有机酸形成的盐,所述有机酸包括:乙酸、柠檬酸、乳酸、丙二酸、马来酸、酒石酸、延胡索酸、苯甲酸、天冬氨酸、谷氨酸、琥珀酸、油酸、三氟乙酸、草酸、扑酸或葡萄糖酸;可选地,所述无机酸包括:盐酸、硫酸、硼酸或碳酸。
- 一种美容或药物组合物,其特征在于,包括有效量的权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,以及至少一种赋形剂和任选的美容上或药学上可接受的佐剂;可选地,所述佐剂选自:胶原合成刺激剂、调节PGC-1α合成的剂、调节PPARγ的活性的剂、增加或减少脂肪细胞的甘油三酸酯含量的剂、刺激或延迟脂肪细胞分化的剂、脂解剂或刺激脂肪分解的剂、溶脂剂、生脂剂、乙酰胆碱受体聚集的抑制剂、抑制肌肉收缩的剂、抗胆碱能试剂、弹性蛋白酶抑制剂、基质金属蛋白酶抑制剂、黑色素合成刺激或抑制剂、增 白剂或脱色剂、促色素沉着剂、自晒黑剂、抗老化剂、NO-合酶抑制剂、5α-还原酶抑制剂、赖氨酰羟化酶和/或脯氨酰羟化酶的抑制剂、抗氧化剂、自由基清除剂和/或抗大气污染的剂、活性羰基类物质清除剂、抗糖化剂、抗组胺剂、抗病毒剂、抗寄生虫剂、乳化剂、润肤剂、有机溶剂、液体推进剂、皮肤调理剂、保湿剂、保留水分的物质、α羟基酸、β羟基酸、增湿剂、表皮水解酶、维生素、氨基酸、蛋白质、色素或着色剂、染料、生物聚合物、胶凝聚合物、增稠剂、表面活性剂、软化剂、粘合剂、防腐剂、抗皱剂、能够减少或治疗下眼袋的剂、去角质剂、角质剥离剂、角质层分离剂、抗微生物剂、抗真菌剂、抑真菌剂、灭菌剂、抑菌剂、刺激真皮或表皮大分子的合成和/或能够抑制或预防它们的降解的剂、刺激弹性蛋白合成的剂、刺激核心蛋白聚糖合成的剂、刺激层粘连蛋白合成的剂、刺激防御素合成的剂、刺激伴侣蛋白合成的剂、刺激cAMP合成的剂、热休克蛋白、刺激HSP70合成的剂、刺激热休克蛋白合成的剂、刺激透明质酸合成的剂、刺激纤连蛋白合成的剂、刺激去乙酰化酶合成的剂、刺激脂质和角质层组分的合成的剂、神经酰胺、脂肪酸、抑制胶原降解的剂、抑制弹性蛋白降解的剂、抑制丝氨酸蛋白酶的剂、刺激成纤维细胞增殖的剂、刺激角质形成细胞增殖的剂、刺激脂肪细胞增殖的剂、刺激黑色素细胞增殖的剂、刺激角质形成细胞分化的剂、抑制乙酰胆碱酯酶的剂、皮肤松弛剂、刺激糖胺聚糖合成的剂、抗角化过度剂、粉刺溶解剂、抗银屑病剂、抗皮炎剂、抗湿疹剂、DNA修复剂、DNA防护剂、稳定剂、止痒剂、用于治疗和/或护理敏感性皮肤的剂、固化剂、紧致剂、重构剂、抗拉伸纹剂、粘合剂、调节皮脂产生的剂、止汗剂、刺激愈合的剂、协助愈合的剂、刺激再上皮化的剂、协助再上皮化的剂、细胞因子生长因子、镇静剂、抗炎剂、麻醉剂、作用于毛细血管循环和/或微循环的剂、刺激血管生成的剂、抑制血管渗透性的剂、静脉紧张剂、作用于细胞代谢的剂、用于改善真皮-表皮接合的剂、诱导毛发生长的剂、毛发生长抑制或延缓剂、香料、螯合剂、植物提取物、精油、海洋提取物、得自生物发酵过程的剂、无机盐、细胞提取物、防晒剂、以及有效抗A和/或B紫外线的有机或无机光防护剂或其混合物。
- 根据权利要求8所述的美容或药物组合物,其特征在于,所述美容或药物组合物的制剂选自:霜剂、油、奶、香膏、泡沫、洗剂、凝胶、擦剂、浆液、皂、洗发精、润发乳、血清、软膏、摩丝、润发油、粉末、杆剂、笔剂、喷雾剂、气溶胶、胶囊剂、片剂、颗粒剂、口香糖、溶液、混悬液、乳剂、糖浆剂、酏剂、多糖薄膜、胶冻或明胶;可选地,所述胶囊剂包括:软胶囊剂、硬胶囊剂,可选为明胶胶囊剂;可选地,所述片剂包括:糖衣片剂。
- 一种美容上或药学上可接受的递送***或缓释***,其特征在于,包含有效量的权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述的美容或药物组合物;所述美容上或药学上可接受的递送***或缓释***选自:脂质体、油质体、非离子型表面活性剂脂质体囊泡、醇质体、毫米胶囊、微米胶囊、纳米胶囊、纳米结构的脂质载体、海绵状物、环糊精、类脂囊泡、胶束、毫米球、微米球、纳米球、脂质球、微米乳液、纳米乳液、毫米粒子、微米粒子或纳米粒子;可选为脂质体或微米乳液,可选具有反胶束的内部结构的油包水型微米乳液。
- 一种美容上或药学上可接受的固体有机聚合物或固体无机支撑体,其特征在于,包含有效量的权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述的美容或药物组合物;所述美容上或药学上可接受的固体有机聚合物或固体无机支撑体选自:滑石、膨润土、二氧化硅、淀粉或麦芽糖糊精。
- 一种化妆品,其特征在于,包含有效量的权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述的美容或药物组合物;可选地,所述化妆品选自:遮瑕膏、粉底、卸妆液、卸妆乳、眼影、唇棒、唇彩、护唇膏或唇粉。
- 一种织物、无纺织物或医学装置,其特征在于,包含有效量的权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述的美容或药物组合物;可选地,所述织物、无纺织物或医学装置选自:绷带、纱布、t-恤衫、短袜、裤袜、内衣、腰带、手套、尿布、卫生巾、敷裹物、床罩、擦拭巾、粘附贴剂、非粘附贴剂、封闭贴剂、微电子贴剂或面膜。
- 权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述美容或药物 组合物,或权利要求10所述的美容上或药学上可接受的递送***或缓释***,或权利要求11所述的美容上或药学上可接受的固体有机聚合物或固体无机支撑体,或权利要求12所述的化妆品,或权利要求13所述的织物、无纺织物或医学装置在制备用于治疗或护理皮肤或粘膜的美容组合物或药用组合物中的用途。
- 权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述美容或药物组合物,或权利要求10所述的美容上或药学上可接受的递送***或缓释***,或权利要求11所述的美容上或药学上可接受的固体有机聚合物或固体无机支撑体,或权利要求12所述的化妆品,或权利要求13所述的织物、无纺织物或医学装置在制备用于治疗或护理体表创伤、烧伤、皮肤溃疡、减少疤痕产生、或加快疤痕修复的美容组合物或药物组合物中的用途。
- 权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述美容或药物组合物,或权利要求10所述的美容上或药学上可接受的递送***或缓释***,或权利要求11所述的美容上或药学上可接受的固体有机聚合物或固体无机支撑体,或权利要求12所述的化妆品,或权利要求13所述的织物、无纺织物或医学装置在制备用于促进成纤维细胞增殖、增加胶原蛋白生成、用于改善皮肤屏障功能、或用于皮肤或粘膜的再上皮化或愈合的美容组合物或药物组合物中的用途。
- 权利要求1-7任一项所述的式(I)所示的肽,或其立体异构体、或立体异构体的混合物、或其美容上可接受的盐、或其药学上可接受的盐,或权利要求8或9所述美容或药物组合物,或权利要求10所述的美容上或药学上可接受的递送***或缓释***,或权利要求11所述的美容上或药学上可接受的固体有机聚合物或固体无机支撑体,或权利要求12所述的化妆品,或权利要求13所述的织物、无纺织物或医学装置在制备用于治疗、预防或修复皮肤老化或光老化的美容组合物或药物组合物中的用途。
- 根据权利要求17所述的用途,其中,皮肤老化或光老化的治疗、预防或修复是减少、预防或治疗面部皱纹。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020247007789A KR20240042649A (ko) | 2021-08-12 | 2021-08-12 | 합성 펩티드, 화장료 조성물 또는 약학 조성물 및 그의 사용 |
CN202180069751.7A CN116829169A (zh) | 2021-08-12 | 2021-08-12 | 一种合成肽以及它们的美容组合物或药用组合物及用途 |
PCT/CN2021/112345 WO2023015533A1 (zh) | 2021-08-12 | 2021-08-12 | 一种合成肽以及它们的美容组合物或药用组合物及用途 |
EP21953150.6A EP4385516A1 (en) | 2021-08-12 | 2021-08-12 | Synthetic peptide, and cosmetic composition or pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/112345 WO2023015533A1 (zh) | 2021-08-12 | 2021-08-12 | 一种合成肽以及它们的美容组合物或药用组合物及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023015533A1 true WO2023015533A1 (zh) | 2023-02-16 |
Family
ID=85199780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/112345 WO2023015533A1 (zh) | 2021-08-12 | 2021-08-12 | 一种合成肽以及它们的美容组合物或药用组合物及用途 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4385516A1 (zh) |
KR (1) | KR20240042649A (zh) |
CN (1) | CN116829169A (zh) |
WO (1) | WO2023015533A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440248A (zh) * | 2023-03-31 | 2023-07-18 | 广州市尊爱日用化妆品有限公司 | 含肽和羟丙基四氢吡喃三醇外用制剂组合物及其制备方法 |
CN117106021A (zh) * | 2023-10-25 | 2023-11-24 | 深圳市维琪科技股份有限公司 | 六肽及其组合物和用途 |
CN117304265A (zh) * | 2023-11-29 | 2023-12-29 | 深圳市维琪科技股份有限公司 | 一种皮肤护理多肽、组合物及其应用 |
CN117417408A (zh) * | 2023-12-14 | 2024-01-19 | 深圳市维琪科技股份有限公司 | 一种抗衰六肽及其组合物和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657845A (zh) * | 2012-05-31 | 2012-09-12 | 中国科学院昆明动物研究所 | 无指盘臭蛙促皮肤修复多肽ah90和cw49的应用 |
CN106038351A (zh) * | 2016-07-12 | 2016-10-26 | 深圳市维琪医药研发有限公司 | 一种用于淡化皱纹的多肽组合物 |
EP3546478A1 (en) * | 2018-03-26 | 2019-10-02 | Uniwersytet Gdanski | New peptide derivatives of platelet derived growth factor (pdgf), a method for their preparation, pharmaceutical compositions containing them and application of these compositions |
WO2020152568A1 (en) * | 2019-01-21 | 2020-07-30 | Globetech Innovation S.R.O. | Skin renewing and healing mixture of peptide components and its use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2349972B1 (es) * | 2009-02-16 | 2011-11-24 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas. |
-
2021
- 2021-08-12 CN CN202180069751.7A patent/CN116829169A/zh active Pending
- 2021-08-12 WO PCT/CN2021/112345 patent/WO2023015533A1/zh active Application Filing
- 2021-08-12 KR KR1020247007789A patent/KR20240042649A/ko unknown
- 2021-08-12 EP EP21953150.6A patent/EP4385516A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657845A (zh) * | 2012-05-31 | 2012-09-12 | 中国科学院昆明动物研究所 | 无指盘臭蛙促皮肤修复多肽ah90和cw49的应用 |
CN106038351A (zh) * | 2016-07-12 | 2016-10-26 | 深圳市维琪医药研发有限公司 | 一种用于淡化皱纹的多肽组合物 |
EP3546478A1 (en) * | 2018-03-26 | 2019-10-02 | Uniwersytet Gdanski | New peptide derivatives of platelet derived growth factor (pdgf), a method for their preparation, pharmaceutical compositions containing them and application of these compositions |
WO2020152568A1 (en) * | 2019-01-21 | 2020-07-30 | Globetech Innovation S.R.O. | Skin renewing and healing mixture of peptide components and its use |
Non-Patent Citations (14)
Title |
---|
"Commission of Biochemical Nomenclature", EUROPEAN JOURNAL OF BIOCHEMISTRY (EUR.J.BIOCHEM., vol. 138, 1984, pages 9 - 37 |
"CTFA International Cosmetic Ingredient Dictionary & Handbook", 2008 |
BIOCHEMICAL NOMENCLATURE COMMISSION OF IUPAC-IUB IN EUR J. BIOCHEM., vol. 138, 1984, pages 9 - 37 |
HIPLER U.C. AND ELSNER P. S. KARGER A.G.: "Curr. Probl. Dermatol.", vol. 33, 2006, BASEL, article "Biofunctional Textiles and the Skin" |
J. CHEM, vol. 264, 1989, pages 633 - 673 |
KULLMANN W.: "Proteases as catalysts for enzymic syntheses of opioid peptides", BIOCHEMICAL JOURNAL (J. BIOL. CHEM., vol. 255, 1980, pages 8234 - 8238, XP002263435 |
LIU HAN, DUAN ZILEI, TANG JING, LV QIUMIN, RONG MINGQIANG, LAI REN: "A short peptide from frog skin accelerates diabetic wound healing", THE FEBS JOURNAL, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 281, no. 20, 1 October 2014 (2014-10-01), GB , pages 4633 - 4643, XP093034901, ISSN: 1742-464X, DOI: 10.1111/febs.12968 * |
LLOYD-WILLIAMS P.ALBERICIO F.GIRALT E.: "Convergent Solid Phase Peptide Synthesis", TETRAHEDRON, vol. 49, 1993, pages 11065 - 11133, XP002047668, DOI: 10.1016/S0040-4020(01)81800-7 |
LLOYD-WILLIAMS P.ALBERICIO F.GIRALT E.: "Peptides and Chemical Approaches to the Synthesis of Peptides and Proteins", 1997, CRC |
MALCOM R.K.MCCULLAGH S.D.WOOLFSON A.D.GORMAN S.P.JONES D.S.CUDDY J.: "Controlled release of a model antibacterial drug from a novel self lubricating silicone (from a novel self lubricating silicone Controlled release of antimicrobial drug models from lubricated silicone biomaterials", J.CONT.RELEASE, vol. 97, 2004, pages 313320 |
MIBELLE, BIOCHEMISTRY |
NELSON G.: "Application of microencapsulation in textiles (microencapsulation in textiles", INT. J. PHARM., vol. 242, 2002, pages 5562 |
SCHAAB C.K.: "Impregnating Fabrics With Microcapsules (using microcapsules to impregnate fabrics", 1986, HAPPI |
WILKINSON J.B.: "Harry's Cosmetology", 1982, LONGMAN HOUSE |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116440248A (zh) * | 2023-03-31 | 2023-07-18 | 广州市尊爱日用化妆品有限公司 | 含肽和羟丙基四氢吡喃三醇外用制剂组合物及其制备方法 |
CN116440248B (zh) * | 2023-03-31 | 2024-03-12 | 广州市尊爱日用化妆品有限公司 | 含肽和羟丙基四氢吡喃三醇外用制剂组合物及其制备方法 |
CN117106021A (zh) * | 2023-10-25 | 2023-11-24 | 深圳市维琪科技股份有限公司 | 六肽及其组合物和用途 |
CN117106021B (zh) * | 2023-10-25 | 2023-12-26 | 深圳市维琪科技股份有限公司 | 六肽及其组合物和用途 |
CN117304265A (zh) * | 2023-11-29 | 2023-12-29 | 深圳市维琪科技股份有限公司 | 一种皮肤护理多肽、组合物及其应用 |
CN117304265B (zh) * | 2023-11-29 | 2024-01-30 | 深圳市维琪科技股份有限公司 | 一种皮肤护理多肽、组合物及其应用 |
CN117417408A (zh) * | 2023-12-14 | 2024-01-19 | 深圳市维琪科技股份有限公司 | 一种抗衰六肽及其组合物和用途 |
CN117417408B (zh) * | 2023-12-14 | 2024-02-13 | 深圳市维琪科技股份有限公司 | 一种抗衰六肽及其组合物和用途 |
Also Published As
Publication number | Publication date |
---|---|
KR20240042649A (ko) | 2024-04-02 |
EP4385516A1 (en) | 2024-06-19 |
CN116829169A (zh) | 2023-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7010823B2 (ja) | 皮膚、毛髪、爪および/または粘膜の処置および/またはケアにおいて有用な化合物 | |
JP7227903B2 (ja) | 皮膚、毛髪、爪および/もしくは粘膜の処置ならびに/またはケアに有用な化合物 | |
AU2012234366B2 (en) | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
WO2023015533A1 (zh) | 一种合成肽以及它们的美容组合物或药用组合物及用途 | |
KR102260346B1 (ko) | 피부 치료 및/또는 관리에 유용한 화합물 및 이의 미용 또는 약제 조성물 | |
KR102285933B1 (ko) | 피부, 모발 및/또는 점막의 치료 및/또는 관리에 유용한 화합물 및 이들의 미용적 또는 약제학적 조성물 | |
CA2751436C (en) | Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions | |
EP2838547B1 (en) | Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
AU2009218680B2 (en) | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors | |
JP5818356B2 (ja) | 皮膚、粘膜、頭皮、及び/若しくは毛髪の処置及び/若しくはケアに有用なペプチド並びに/又は化粧品組成物若しくは医薬組成物におけるその使用 | |
KR101988676B1 (ko) | Pgc-1알파 조절 펩티드 | |
JP2020525529A (ja) | 皮膚、毛髪、爪および/または粘膜の処置および/またはケアに有用な化合物 | |
JP2013508322A (ja) | 皮膚、粘膜および/または毛髪の治療および/またはケアに使用するペプチド、ならびに化粧料または医薬品組成物におけるその使用 | |
WO2024109878A1 (zh) | 具有抗衰老作用的肽及其组合物和用途 | |
JP2021534134A (ja) | 皮膚、毛髪、爪および/または粘膜の処置および/またはケアに有用な化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21953150 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180069751.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18682510 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2024106100 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021953150 Country of ref document: EP Effective date: 20240312 |